Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim in mild-to-moderate Alzheimer's Disease
NCT04902703Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Sargramostim with Placebo Control - Saline (2 arms). Primary endpoint: Adverse Events at 38 weeks. Started Jun 2022; status: recruiting.
02
Drugs
sargramostim
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04902703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902703.